
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The use of highly active antiretroviral therapy by pregnant HIV-positive women does not cause congenital abnormalities in the women's infants, but the anti-HIV drugs were linked with a likelihood of premature delivery, according to the results of a 14-year survey presented at the Seventh International Congress on Drug Therapy in HIV Infection. The study, conducted by U.K. and Irish researchers, examined more than 3,800 HIV-positive women and their infants from 1990 to 2003. Since 2001, when triple-drug therapy became commonplace, 13% of the deliveries were premature, coming before 37 weeks of gestation (the normal average is 40 weeks or more). HIV-positive pregnant women on combination therapy were found to be 1.47 times more likely to deliver early, according to the study. But congenital abnormalities were seen in only about 3% of the babies, about the same rate as seen in the general population.
From our Sponsors
Most Popular
Plus: Featured Video